Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
New Phase II data show vast majority of patients experiencing no relapses or disability progression
Phase 3 study results will form the basis for future discussions with global regulatory authorities
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Several late-stage pipeline products have the potential to address some of these unmet needs
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
In addition, common light chain antibodies generated by RenLite mice can greatly improve the efficiency of downstream assembly of complex drug molecules such as bispecific antibodies and bispecific antibody-drug conjugates (bsADCs)
With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Subscribe To Our Newsletter & Stay Updated
